Therapeutic blockade of CXCR2 rapidly clears inflammation in arthritis and atopic dermatitis models: demonstration with surrogate and humanized antibodies
Jahangir Alam, Liang Xie, Caroline Ang, Farnaz Fahimi, Stephen B. Willingham, Andrew J. Kueh, Marco J. Herold, Charles R. Mackay, R. Robert
Abstract
studies, we developed a surrogate anti-mouse CXCR2 antibody, as well as a human knock-in CXCR2 mouse. When administered in models of atopic dermatitis (AD) and rheumatoid arthritis (RA), the antibodies rapidly clear inflammation. Our findings support further developments of anti-CXCR2 mAb approaches not only for RA and AD, but also for other neutrophil-mediated inflammatory conditions where neutrophils are pathogenic and medical needs are unmet.
Topics & Concepts
ImmunologyMedicineInflammationHumanized mouseRheumatoid arthritisCXC chemokine receptorsMonoclonal antibodyChemokineAtopic dermatitisArthritisImmune systemAntibodyChemokine receptorDermatology and Skin DiseasesAsthma and respiratory diseasesT-cell and B-cell Immunology